US President Donald Trump announced tariffs on branded drugs on October 1. However, White House sources have clarified that there are no plans to impose tariffs on Indian generic drugs. Citing a Wall Street Journal report, spokeswoman Kush Desai stated that the Trump administration is not considering tariffs on generics under Section 232 at this time.